Our Products
Loans
Cards
Insurance
Investment
Stock Market
Electronics Mall
CIBIL Score
Knowledge Centre
Academy 
Calculators
Our Services
My Account
Do not call
En
Syncom Formulations (India) Ltd. Share Price
Day's Range
Day's Range
Low
₹14.22
High
₹14.59
Price Summary
| Previous Close | ₹14.31 |
|---|---|
| Day's Range | ₹14.22 - ₹14.59 |
| Open | ₹14.35 |
| 52 Week Range | ₹10.21 - ₹19.50 |
| Volume | 12,54,289 |
| Market Cap | ₹0.00 |
| Previous Close | ₹14.28 |
|---|---|
| Day's Range | ₹14.24 - ₹14.60 |
| Open | ₹14.43 |
| 52 Week Range | ₹10.21 - ₹19.44 |
| Volume | 1,33,527 |
| Market Cap | ₹0.00 |
Stocks Summary
| Trade Value ( ₹ in Lacs) | 179.49 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 17.52 |
| TTM EPS (₹) | 0.81 |
| P/E Ratio | 31.28 |
| Book Value(₹) | 3.23 |
| PAT Margin (%) | 10.63 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 18.77 |
| Trade Value ( ₹ in Lacs) | 19.07 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 17.52 |
| TTM EPS (₹) | 0.81 |
| P/E Ratio | 31.28 |
| Book Value(₹) | 3.23 |
| PAT Margin (%) | 10.63 |
| Face Value (₹) | 1.00 |
| ROCE(%) | 18.77 |
Financials
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 4628.49 | 1484.63 |
| Expenses | N/A | N/A |
| PBT | 646.59 | 230.07 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 488.72 | 175.02 |
About Syncom Formulations (India) Ltd.
| Founded | 1988 |
|---|---|
| Managing Director | Vijay Shankarlal Bankda |
| NSE Symbol | SYNCOMF |
Peer Comparision
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | 4,46,924.12 | 1,869.75 | 1,548.00 - 1,548.00 |
| Divi's Laboratories Ltd. | 1,74,618.60 | 6,560.00 | 5,636.50 - 5,636.50 |
| Torrent Pharmaceuticals Ltd. | 1,56,449.79 | 4,636.90 | 3,287.30 - 3,287.30 |
| Apollo Hospitals Enterprise Ltd. | 1,24,925.14 | 8,615.70 | 6,696.50 - 6,696.50 |
| Cipla Ltd. | 1,18,361.46 | 1,458.60 | 1,165.70 - 1,165.70 |
| Dr. Reddy's Laboratories Ltd. | 1,13,252.99 | 1,342.80 | 1,148.40 - 1,148.40 |
| Zydus Lifesciences Ltd. | 1,10,942.38 | 1,106.80 | 835.50 - 835.50 |
| Lupin Ltd. | 1,10,657.13 | 2,398.70 | 1,836.80 - 1,836.80 |
| Max Healthcare Institute Ltd. | 1,09,908.42 | 1,139.45 | 903.00 - 903.00 |
| Mankind Pharma Ltd. | 1,05,169.43 | 2,499.60 | 1,909.70 - 1,909.70 |
No Records Found
Latest News
Mankind Pharma informs about press release
Pharmaids Pharmaceuticals informs about outcome of board meeting
Pursuant Regulation 30 read with Schedule III of Listing Regulations, Pharmaids Pharmaceuticals has informed that the Board of Directors of the Company at their meeting held on Tuesday, June 30, 2026, have, basis recommendation of the Audit Committee, considered and approved the appointment of V Mahendra & Associates Chartered Accountants (FRN: 025356S) as Internal Auditors of the Company for carrying out the Internal Audit for the financial year 2026-27. The disclosure as required under Regulation 30 of the Listing Regulations read with SEBI Master Circular dated January 30, 2026, is enclosed as Annexure A. The above Information is being made available on the Company’s website: www.pharmaids.com.
The above information is a part of company’s filings submitted to BSE.
Mankind Pharma submits AGM notice
Hexagon Nutrition - Quaterly Results
| (Rs. in Million) |
| Quarter ended | Year to Date | Year ended | |||||||
| 202603 | 202503 | % Var | 202603 | 202503 | % Var | 202603 | 202503 | % Var | |
| Sales | 984.71 | 834.53 | 18.00 | 3191.20 | 2674.47 | 19.32 | 3191.20 | 2674.47 | 19.32 |
| Other Income | 61.50 | 22.21 | 176.90 | 152.14 | 100.82 | 50.90 | 152.14 | 100.82 | 50.90 |
| PBIDT | 201.48 | 108.02 | 86.52 | 585.13 | 438.24 | 33.52 | 585.13 | 438.24 | 33.52 |
| Interest | 6.24 | 5.18 | 20.46 | 18.82 | 21.03 | -10.51 | 18.82 | 21.03 | -10.51 |
| PBDT | 198.44 | 102.66 | 93.30 | 569.87 | 414.60 | 37.45 | 569.87 | 414.60 | 37.45 |
| Depreciation | 16.46 | 13.49 | 22.02 | 57.44 | 49.88 | 15.16 | 57.44 | 49.88 | 15.16 |
| PBT | 181.98 | 89.17 | 104.08 | 512.43 | 364.72 | 40.50 | 512.43 | 364.72 | 40.50 |
| TAX | 45.65 | 22.76 | 100.57 | 130.95 | 95.03 | 37.80 | 130.95 | 95.03 | 37.80 |
| Deferred Tax | 0.14 | -1.39 | -110.07 | -2.08 | -1.72 | 20.93 | -2.08 | -1.72 | 20.93 |
| PAT | 136.33 | 66.41 | 105.29 | 381.48 | 269.69 | 41.45 | 381.48 | 269.69 | 41.45 |
| Equity | 110.63 | 110.63 | 0.00 | 110.63 | 110.63 | 0.00 | 110.63 | 110.63 | 0.00 |
| PBIDTM(%) | 20.46 | 12.94 | 58.07 | 18.34 | 16.39 | 11.90 | 18.34 | 16.39 | 11.90 |
Bharat Parenterals informs about disclosure
No Records Found
Sign in to Unlock Offers!
We don't SPAM
Frequently Asked Questions
The current share price of Syncom Formulations (India) Ltd. is ₹14.31 as of 2026-07-01.
The market capitalisation of Syncom Formulations (India) Ltd. is ₹1,339.50 as of 2026-06-30.
The 1-year return of Syncom Formulations (India) Ltd. is -4.94% as of 2026-07-01.
The P/E ratio of Syncom Formulations (India) Ltd. is 31.28 as of 2026-07-01.
The 52-week high and low of Syncom Formulations (India) Ltd. are ₹19.50 and ₹10.21, respectively, as of 2026-07-01.
Disclaimer
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.
